Fusidine | Fusidic acid | 6990-06-3 Active Pharmaceutical Ingredients of Antibiotics. Fusidic acid антибиотик

Fusidic acid - Wikipedia

Fusidic acid is a steroid antibiotic that is often used topically in creams and eyedrops but may also be given systemically as tablets or injections. The global problem of advancing antimicrobial resistance has led to a renewed interest in its use recently.[1]

Pharmacology[edit]

Fusidic acid acts as a bacterial protein synthesis inhibitor by preventing the turnover of elongation factor G (EF-G) from the ribosome. Fusidic acid is effective primarily on gram-positive bacteria such as Staphylococcus species, Streptococcus species,[2] and Corynebacterium species. Fusidic acid inhibits bacterial translation and does not kill the bacteria, and is therefore termed "bacteriostatic".

Fusidic acid is a steroid antibiotic, derived from the fungus Fusidium coccineum and was developed by Leo Pharma in Ballerup, Denmark and released for clinical use in the 1960s. It has also been isolated from Mucor ramannianus and Isaria kogana. The drug is licensed for use as its sodium salt sodium fusidate, and it is approved for use under prescription in South Korea, Japan, UK, Canada, Europe, Australia, New Zealand, Thailand, India and Taiwan. A different oral dosing regimen, based on the compound's pharmacokinetic/pharmacodynamic (PK-PD) profile is in clinical development in the U.S.[3] as Taksta.

Fusidic acid is active in vitro against Staphylococcus aureus, most coagulase-positive staphylococci, Beta-hemolytic streptococci, Corynebacterium species, and most clostridium species. Fusidic acid has no known useful activity against enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila, and Bacteroides fragilis). Fusidic acid is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.

One important clinical use of fusidic acid is its activity against methicillin-resistant Staphylococcus aureus (MRSA).[4] Although many strains of MRSA remain sensitive to fusidic acid, there is a low genetic barrier to drug resistance (a single point mutation is all that is required), fusidic acid should never be used on its own to treat serious MRSA infection and should be combined with another antimicrobial such as rifampicin when administering oral or topical dosing regimens approved in Europe, Canada, and elsewhere. However, resistance selection is low when pathogens are challenged at high drug exposure.[5] An orally-administered mono-therapy with a high loading dose is under development in the United States.[3]

Topical fusidic acid is occasionally used as a treatment for acne vulgaris.[6] As a treatment for acne, fusidic acid is often partially effective at improving acne symptoms.[7] However, research studies have indicated that fusidic acid is not as highly active against Propionibacterium acnes as many other antibiotics that are commonly used as acne treatments.[8] Fusidic acid is also found in several additional topical skin and eye preparations (e.g. Fucibet), although its use for these purposes is controversial.[9]

Fusidic acid is being tested for indications beyond skin infections. There is evidence from compassionate use cases that fusidic acid may be effective in the treatment of patients with prosthetic joint-related chronic osteomyelitis.[10]

Fusidic acid should not be used on its own to treat S. aureus infections when used at low drug dosages. However, it may be possible to use fusidic acid as monotherapy when used at higher doses.[3] The use of topical preparations (skin creams and eye ointments) containing fusidic acid is strongly associated with the development of resistance,[11] and there are voices advocating against the continued use of fusidic acid monotherapy in the community.[9] Topical preparations used in Europe often contain fusidic acid and gentamicin in combination, which helps to prevent the development of resistance.

Depending on the reason for which sodium fusidate is prescribed, the adult dose can be 250 mg twice a day and or up to 750 mg three times a day. (Skin conditions normally need the smaller dose). It is available in tablet and suspension form.[12] A oral dosing regimen is in clinical development in the U.S. based on the pharmacokinetic/pharmacodynamic profile of the compound. It incorporates a dose of 1,500 mg twice on the first day followed by 600 mg twice-daily. It has been demonstrated in an in vitro model to have a low potential for selection of resistant organisms.[3]

There is an intravenous preparation available, but it is irritant to veins, causing phlebitis. Most people absorb the drug extremely well after taking it orally, so, if a patient can swallow, there is not much need to administer it intravenously, even if used to treat endocarditis (infection of the heart chambers).

Cautions[edit]

There is inadequate evidence of safety in human pregnancy. Animal studies and many years of clinical experience suggest that fusidic acid is devoid of teratogenic effects (birth defects), but fusidic acid can cross the placental barrier.[13]

Side-effects[edit]

Fucidin tablets and suspension, whose active ingredient is sodium fusidate, occasionally cause liver upsets, which can produce jaundice (yellowing of the skin and the whites of the eyes). This condition will almost always get better after the patient finishes taking Fucidin tablets or suspension. Other related side-effects include dark urine and lighter-than-usual feces. These, too, should normalize when the course of treatment is completed.[14] Patients taking the drug should tell their doctors if they notice these side effects.

Resistance[edit]

In vitro susceptibility studies of U.S. strains of several bacterial species such as S. aureus, including MRSA and coagulase negative Staphylococcus, indicate potent activity against these pathogens[15][16][17]

In the UK and Australia, susceptibility is defined as a minimum inhibitory concentration (MIC) of 0.25 mg/l or 0.5 mg/l or less. Resistance is defined as an MIC of 2 mg/l or more. In laboratories using disc diffusion methods, susceptibility for a 2.5 µg disc is defined as a zone of 22 mm or more, and resistance is defined as a zone of 17 mm or less; intermediate values are defined as intermediate resistance. These susceptibility criteria are based on lower dosing regimens used outside of the U.S. Clinical trials in the U.S. incorporate a different dosing regimen that results in higher blood levels. Therefore, the U.S. dosing regimen may warrant different susceptibility criteria.

Mechanisms of resistance have been extensively studied only in Staphylococcus aureus. The most important mechanism is the development of point mutations in fusA, the chromosomal gene that codes for EF-G. The mutation alters EF-G so that fusidic acid is no longer able to bind to it.[18][19] Resistance is readily acquired when fusidic acid is used alone and commonly develops during the course of treatment. As with most other antibiotics, resistance to fusidic acid arises less frequently when used in combination with other drugs. For this reason, fusidic acid should not be used on its own to treat serious Staph. aureus infections. However, at least in Canadian hospitals, data collected between 1999-2005 showed rather low rate of resistance of MSSA and MRSA to fusidic acid, and mupirocin was found to be the more problematic topical antibiotic for the aforementioned conditions.[20]

Some bacteria also mediate resistance via the fusB gene, which is carried on a plasmid; the mechanism by which fusB causes resistance is unknown.

Interactions[edit]

Fusidic acid should not be used with quinolones, with which they are antagonistic. When combined with rifampicin, the action of fusidic acid is additive or synergistic.[21]It has been reported on August 8, 2008, that the Irish Medicines Board was investigating the death of a 59-year-old Irish man who developed rhabdomyolysis after combining atorvastatin and Fusidic Acid, and three similar cases.[22] In August, 2011, the UK's Medicines and Healthcare products Regulatory Agency issued a Drug Safety Update warning that "Systemic fusidic acid (Fucidin) should not be given with statins because of a risk of serious and potentially fatal rhabdomyolysis. "[23]

It is delivered as an ointment, as a cream, as eye drops, or in tablet form.

Trade names and preparations[edit]

• Usidin cream(in Pakistan, Pacific Pharmaceuticals Ltd. )
• Fucidin (of Leo in Canada )
• Fucidin H (topical cream with corticosteroid - Leo)
• Fucidin (of Leo in UK/ Leo-Ranbaxy-Croslands in India)
• Fucidine (of Leo in France)
• Fucidin (of Leo in Norway and Israel)
• Fucidin (of Adcock Ingram, licensed from Leo, in South Africa)
• Fucithalmic (of Leo in the UK, the Netherlands, Denmark and Portugal)
• Fucicort (topical mixture with hydrocortisone)
• Fucibet (fusidic acid/betamethasone valerate topical cream)
• Ezaderm (topical mixture with betamethasone)(of United Pharmaceutical "UPM" in Jordan)
• Fuci (of pharopharm in Egypt)
• Fucizon (topical mixture with hydrocortisone of pharopharm in Egypt)
• Foban (topical cream in New Zealand)
• Betafusin (usidic acid/betamethasone valerate topical cream in Greece)
• Fusimax (of Roussette in India)
• Fusiderm (topical cream and ointment by Indi Pharma in India)
• Fusid (in Nepal)
• Fudic (topical cream in India)
• Fucidin (후시딘, of Dong Wha Pharm in South Korea)
• Dermy (Topical cream of W. Woodwards in Pakistan)
• Fugen Cream (膚即淨軟膏 in Taiwan)
• Phudicin Cream (in China; 夫西地酸[24])
• Fucidin Fusidic Acid (in China;夫西地酸 of Leo Laoratories Limited)
• Dermofucin cream, ointment and gel (in Jordan)
• Optifucin viscous eye drops (of API in Jordan)
• Verutex (of Roche in Brazil)
• Taksta (of Cempra in U.S. For export only in US)
• Futasole (of Julphar in Gulf and north Africa)
• Stanicid (2% ointment of Hemofarm in Serbia)
• Staphiderm Cream (Israel. By Trima).
• Fuzidin (tablets of Biosintez in Russia)
• Fuzimet (ointment with methyluracil of Biosintez in Russia)
• Axcel Fusidic Acid (2% cream and ointment of Kotra Pharma, Malaysia)
• Ofusidic (gydrogel eye drops) produced by Orchidia pharmaceutical in Egypt

References[edit]

1. ^ Falagas ME, Grammatikos AP, Michalopoulos A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther. 2008; 6(5):593-600 doi:10.1586/14787210.6.5.593 PMID 18847400
2. ^ Leclercq, R; Bismuth, R; Casin, I; Cavallo, JD; Croize, J; Felten, A; Goldstein, F; Monteil, H; Quentin-Noury, C; Reverdy, M; Vergnaud, M; Roiron, R (2000). "In Vitro Activity of Fusidic Acid Against Streptococci isolated form Skin and Soft Tissue Infections". J. Antimicrob. Chemother. 45 (1): 27–29. doi:10.1093/jac/45.1.27. 
3. ^ a b c d Moriarty SR, Clark K, Scott D, Degenhardt TP, Fernandes P, Craft JC, Corey GR, Still JG and Das A (2010). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract L1-1762
4. ^ Existing drug will cure hospital superbug MRSA, say scientists – The Guardian, 17 January 2007.Accessed 2008-01-17.
5. ^ O'Neill, AJ; Chopra, I (2004). "Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin. Investig". Drugs. 13 (8): 1045–1063. doi:10.1517/13543784.13.8.1045. PMID 15268641. 
6. ^ Spelman. (1999). "Fusidic acid in skin and soft tissue infections". International Journal of Antimicrobial Agents. 12 Suppl 2: S59–66. doi:10.1016/s0924-8579(98)00074-0. PMID 10528787. 
7. ^ "Fusidic Acid and Acne Vulgaris". ScienceOfAcne.com. 2011-09-11. Retrieved 2012-08-14. 
8. ^ Sommer; et al. (1997). "Investigation of the mechanism of action of 2% fusidic acid lotion in the treatment of acne vulgaris". Clinical Experimental Dermatology. 22 (5): 211–5. doi:10.1046/j.1365-2230.1997.2530670.x. PMID 9536540. 
9. ^ a b Howden BP, Grayson ML (2006). "Dumb and dumber—the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus". Clin Infect Dis. 42 (3): 394–400. doi:10.1086/499365. PMID 16392088. 
10. ^ Wolfe, CR (2011) Case report: treatment of chronic osteomyelitis. Clinical Infectious Diseases 52(Supplement 7): S538-S541
11. ^ Mason BW, Howard AJ, Magee JT (2003). "Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing". J Antimicrob Chemother. 51 (4): 300–3. doi:10.1093/jac/dkg190. PMID 12654748. 
12. ^ Fucidin data sheet archived by New Zealand government. December 2005 Archived 2007-10-26 at the Wayback Machine..Accessed: 2007-09-09.
13. ^ Fucidin) UK data sheet archived at the electronic Medicines Compendium. June 1997.Accessed: 2007-09-09.
14. ^ Fucidin patient information leaflet, archived by Government of Victoria, Australia. Accessed: 2007-09-09.
15. ^ Castanheira, M; Watters, AA; Bell, JM; Turnidge, JD; Jones, RN (2010). "Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008". Antimicrobial Agents and Chemotherapy. 54: 3614–3617. doi:10.1128/aac.01390-09. 
16. ^ Pfaller, M; Castaneira, M; Sader, H; Jones, R (2010). "Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada". International Journal of Antimicrobial Agents. 35: 282–287. doi:10.1016/j.ijantimicag.2009.10.023. 
17. ^ Castanheira M, Mendes RE, Rhomberg PR and Jones RN (2010). Activity of fusidic acid tested against contemporary Staphylococcus aureus collected from United States hospitals. Infectious Diseases Society of America, 48th Annual Meeting, Abstract 226.
18. ^ Turnidge J, Collignon P (1999). "Resistance to fusidic acid". Int J Antimicrob Agents. 12 (Suppl 2): S35–44. doi:10.1016/S0924-8579(98)00072-7. 
19. ^ Besier S, Ludwig A, Brade V, Wichelhaus TA (2003). "Molecular analysis of fusidic acid resistance in Staphylococcus aureus". Mol Microbiol. 47 (2): 463–9. doi:10.1046/j.1365-2958.2003.03307.x. PMID 12519196. 
20. ^ Rennie RP (2006). "Susceptibility of Staphylococcus aureus to fusidic acid:Canadian data". J Cutan Med Surg. 10 (6): 277–280. doi:10.2310/7750.2006.00064. PMID 17241597. 
21. ^ Collignon P, Turnidge J (1999). "Fusidic acid in vitro activity". Int J Antimicrob. 12 (Suppl 2): S45–58. doi:10.1016/S0924-8579(98)00073-9. 
22. ^ Riegel, Ralph (2008-08-08). "Man died after rare medical reaction to cholesterol drug". Irish Independent. 
23. ^ Drug Safety Update Sept 2011, vol 5 issue 2: A1.
24. ^ "Archived copy". Archived from the original on 2011-07-07. Retrieved 2010-09-28. 

External links[edit]

en.wikipedia.org

Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

www.biomedsearch.com

Fusidic acid - wikidoc

Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections.

Pharmacology

Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. Fusidic acid is only effective on gram-positive bacteria such as Staphylococcus species and Corynebacterium species. Fusidic acid inhibits bacterial replication and does not kill the bacteria, and is therefore termed "bacteriostatic".

Fusidic acid is a true antibiotic, derived from the fungus Fusidium coccineum and was developed by Leo Laboratories in Ballerup, Denmark and released for clinical use in the 1960s. It has also been isolated from Mucor ramannianus and Isaria kogana. The drug is not licensed for use in the US, but, as sodium fusidate, it is approved for use under prescription in the UK, Europe Australia and New Zealand.

Uses

Fusidic acid is active in vitro against Staphylococcus aureus, most coagulase-negative staphylococci, Corynebacterium species, most clostridium species. Fusidic acid has no useful activity against streptococci, enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila and Bacteroides fragilis). Fusidic acid is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.

The most important use of fusidic acid clinically is its activity against Methicillin Resistant Staphylococcus Aureus, a sometimes-fatal 'hospital-acquired 'superbug'.[1] Many strains of MRSA remain sensitive to fusidic acid, but because there is a low genetic barrier to resistance (a single point mutation is all that is required), fusidic acid must never be used on its own to treat MRSA and should be combined with another antimicrobial such as rifampicin.

Fusidic acid is often found in topical skin and eye preparations (e.g., Fusibet®), a use which has been contested.[2]

Dosing

Fusidic acid should not be used on its own to treat Staph. aureus infections. The use of topical preparations (skin creams and eye ointments) containing fusidic acid is strongly associated with the development of resistance,[3] and there are voicing agitating against the continued use of fusidic acid monotherapy in the community.[2] Topical preparations used in Europe often contain fusidic acid and gentamicin in combination, which helps to prevent the development of resistance.

Depending on the reason for which sodium fusidate is prescribed the adult dose can be 250 mg twice a day and or up to 750 mg three times a day. (Skin conditions normally need the smaller dose). It is available in tablet and suspension form.[4] There is an intravenous preparation available but it is irritant to veins, causing phlebitis. Most people absorb the drug extremely well after taking it orally so, if a patient can swallow, there is not much need to administer it intravenously, including endocarditis (infection of the heart chambers).

Pregnancy caution

'There is inadequate evidence of safety in human pregnancy. Animal studies and many years of clinical experience suggest that fusidic acid is devoid of teratogenic effects (birth defects)...fusidic acid can cross the placental barrier.[5]

Side Effects

• 'Fucidin®) Tablets and Suspension can occasionally cause liver upsets which can produce jaundice (yellowing of a patient's skin and the whites of his or her eyes). This condition will almost always get better after you finish taking Fucidin®) Tablets or Suspension.

Other related side effects include dark urine, lighter-than-usual feces. These, too should normalize when the course of treatment is completed.'[6]

• Patients taking the drug should tell their doctors if they notice that their urine is 'very dark', their feces is 'very pale' or if their skin or the whites of their eyes becomes yellow, the Australian data sheet for patients adds.

Resistance

Because the drug is not licensed for use in the US, and there are therefore no Clinical and Laboratory Standards Institute standard definitions of fusidic acid resistance.

In the UK and Australia, susceptibility is defined as an MIC of 0.25mg/l or 0.5mg/l or less. Resistance is defined as an MIC of 2mg/l or more. In laboratories using disc diffusion methods, susceptibility for a 2.5µg disc is defined as a zone of 22 mm or more, and resistance is defined as a zone of 17 mm or less; intermediate values are defined as intermediate resistance.

Mechanisms of resistance have only been extensively studied in Staphylococcus aureus. The most important mechanism is the development of point mutations in fusA, the chromosomal gene which codes for EF-G. The mutation alters EF-G so that fusidic acid is no longer able to bind to it.[7][8] Resistance is readily acquired when fusidic acid is used alone and commonly develops during the course of treatment, but resistance does not occur when fusidic acid is used in combination with other antibiotics.[9] For this reason, fusidic acid should not be used on its own to treat Staph. aureus infections.

Some bacteria also mediate resistance via the fusB gene, which is carried on a plasmid; the mechanism by which fusB causes resistance is unknown.

Interactions

Fusidic acid must not be used with quinolones, with which they are antagonistic. When combined with rifampicin, the action of fusidic acid is additive or synergistic.[10]

It is delivered as an ointment, a cream, eye drops or in tablet form.

Trade names and preparations

• Fusidin (of Leo in Canada)
• Fucidin (of Leo in UK/ Leo-Ranbaxy-Croslands in India)
• Fucidine (of Leo in France)
• Fucithalmic (of Leo in UK and Denmark)
• Fucicort (topical mixture with hydrocortisone)
• Fucibet (topical mixture with betamethasone)

References

1. ↑ Existing drug will cure hospital superbug MRSA, say scientists – The Guardian, 17 January 2007.Accessed 2007-09-09.
2. ↑ 2.02.1 Howden BP, Grayson ML. "Dumb and dumber—the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus". Clin Infect Dis. 42 (3): 394–400. 
3. ↑ Mason BW, Howard AJ, Magee JT (2003). "Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing". J Antimicrob Chemother. 51: 300–3. 
4. ↑ Fucidin data sheet archived by New Zealand government. December 2005.Accessed: 2007-09-09.
5. ↑ Fucidin®) UK data sheet archived at the electronic Medicines Compendium. June 1997.Accessed: 2007-09-09.
6. ↑ Fucidin®) patient information leaflet, archived by Government of Victoira, Australia.Accessed: 2007-09-09.
7. ↑ Turnidge J, Collignon P (1999). "Resistance to fusidic acid". Int J Antimicrob Agents. 12 (Suppl 2): S35–44. 
8. ↑ Besier S, Ludwig A, Brade V, Wichelhaus TA (2003). "Molecular analysis of fusidic acid resistance in Staphylococcus aureus". Mol Microbiol. 47: 463–9. 
9. ↑ Fantin B, Leclerq R, Duval J, Carbon C (1993). "Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus". Antimicrob Agents Chemother. 37: 2466–69. 
10. ↑ Collignon P, Turnidge J (1999). "Fusidic acid in vitro activity". Int J Antimicrob. 12 (Suppl 2): S45–58. 

hu:Fuzidinsav nl:Fusidinezuur

www.wikidoc.org

FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic

CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Cempra's investigational antibiotic product candidate, Taksta™ (CEM-102, sodium fusidate, the sodium salt of fusidic acid). The designation is for Taksta oral tablets for the indication of acute bacterial skin and skin structure infections (ABSSSI).

"Taksta is Cempra's second antibiotic product candidate to obtain QIDP status, which should enable us to expedite its development and bring this promising drug to the patients who need it the most," said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. "Previously our lead product, solithromycin, received QIDP status and together we view these designations as further validation of Cempra's progress in achieving its goal of becoming a leader in the global anti-infective market."

The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act of 2012. It provides certain incentives for the development of new anti-infectives, including eligibility for priority review, the FDA's Fast Track program, and a five-year extension of exclusivity under the Hatch-Waxman Act. The FDA has previously granted QIDP designation to Cempra's lead product development candidate solithromycin IV and capsules for the treatment of community acquired bacterial pneumonia (CABP) and solithromycin capsules for the treatment of gonorrhea.

About Taksta™

Cempra is developing Taksta (fusidic acid) exclusively in the U.S. for acute bacterial skin and skin structure infections (ABSSSI) and is exploring its use for the long term oral treatment for refractory bone and joint infections, including prosthetic joint infections. Fusidic acid is orally active against gram-positive bacteria, including all Staphylococcus aureus strains such as HA-MRSA and CA-MRSA. Taksta successfully completed a Phase 2 clinical trial in patients with ABSSSI, which is frequently caused by methicillin-resistant Staphylococcus aureus (MRSA), demonstrating a tolerability profile and efficacy comparable to linezolid (sold under the brand name Zyvox®), the only oral antibiotic with FDA approval for the treatment of MRSA. A Phase 2 trial in patients with primarily staphylococcal infections of prosthetic hip and knee joints demonstrated that fusidic acid in combination with rifampin was generally comparable to intravenous standard of care antibiotics. Based on FDA discussions, Cempra plans to conduct a Phase 3 trial for the treatment of ABSSSI and will conduct an exploratory trial for refractory bone and joint infections. These clinical trials are expected to begin by the end of 2015.

About Cempra, Inc.

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin has also entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta is Cempra's second product candidate, which is being developed for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and also being tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: our and our strategic commercial partners' ability to obtain FDA and foreign regulatory approval of our product candidates; the costs, sources of funds, timing, regulatory review and results of our studies and clinical trials and those of our strategic commercial partners; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our anticipated capital expenditures and our estimates regarding our capital requirements; our ability to commercialize and launch, whether on our own or with a strategic partner, any product candidate that receives regulatory approval; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able to realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; our dependence on the success of solithromycin and Taksta; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

CONTACT: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]

Source:Cempra, Inc.

www.cnbc.com

Fusidic Acid - Drugs.com

In some countries, this medicine may only be approved for veterinary use.

UK matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

D06AX01,D09AA02,J01XC01,S01AA13

CAS registry number (Chemical Abstracts Service)

0006990-06-3

Chemical Formula

C31-h58-O6

Molecular Weight

516

Therapeutic Category

Antibacterial

Chemical Name

29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, (3α,4α,8α,9β,11α,13α,14β,16β,17Z)-

Foreign Names

• Acidum Fusidicum (Latin)
• Fusidinsäure (German)
• Acide fusidique (French)
• Acido fusidico (Spanish)

Generic Names

• Acide fusidique (OS: DCF)
• Fusidic Acid (OS: USAN, BAN)
• SQ 16603 (IS)
• Diethanolamine fusidate (IS)
• Fusidic acid, diolamine (IS)
• Fusidic acid 2,2'-iminodiethanol salt (IS)
• Fusidic acid diethanolamine (IS)
• Acidum fusidicum (PH: Ph. Eur. 8)
• Fusidic Acid (PH: BP 2016)
• Fusidic acid (PH: Ph. Eur. 8)
• Fusidate Sodium (OS: USAN)
• Sodium Fusidate (OS: BANM, JAN)
• Fucidine (IS)
• Fusidic acid, sodium salt (IS)
• Fusidin (IS)
• Fusidinsäure, Natriumsalz (IS)
• Sodium fusidin (IS)
• SQ 16360 (IS)
• ZN 6-Na (IS)
• Natrii fusidas (PH: Ph. Eur. 8)
• Natriumfusidat (PH: Ph. Eur. 8)
• Sodium Fusidate (PH: BP 2016, JP XVI)
• Sodium fusidate (PH: Ph. Eur. 8)
• Sodium, fusidate de (PH: Ph. Eur. 8)

Brand Names

• AcelerSenosiain, Mexico
• Aceler-Co (Fusidic Acid and Betamethasone)Senosiain, Mexico
• Acide Fusidique Arrow 2%Arrow, France
• Acide Fusidique BGR 2%Biogaran, France
• Acide Fusidique Biogaran 2%Biogaran, France
• Acide Fusidique EG 2%EG Labo, France
• Acide Fusidique Mylan 2%Mylan, France
• Acide Fusidique ratiopharm 2%Teva Santé, France
• Acide Fusidique Sandoz 2%Sandoz, France
• Ácido FusídicoGenfar, Peru
• Acido Fusidico 2% MKMK, Colombia
• Acido Fusidico GenfarGenfar, Ecuador
• Ácido Fusídico GenfarGenfar S.A., Costa Rica; Genfar S.A., Dominican Republic; Genfar S.A., Guatemala; Genfar S.A., Honduras; Genfar S.A., Panama; Genfar S.A., El Salvador
• Acido Fusidico IsdinIsdin, Spain
• AcifusinAndrómaco, Argentina
• Acifusin B (Fusidic Acid and Betamethasone)Andrómaco, Argentina
• AffusineWill-Pharma, Belgium
• AfucidFerron, Indonesia
• AfugermISDIN, Italy
• AfusidicOpalia, Tunisia
• Afusidic Plus (Fusidic Acid and Betamethasone)Opalia, Tunisia
• Alpider (Fusidic Acid and Betamethasone)Velka, Greece
• AmficAmros, Pakistan
• ArzimolLazar, Argentina
• Arzimol B (Fusidic Acid and Betamethasone)Lazar, Argentina
• Axcel Fusidic AcidKotra Pharma, Hong Kong; Kotra Pharma, Vietnam
• Axcel Fusidic Acid B (Fusidic Acid and Betamethasone)Kotra Pharma, Vietnam
• Axcel Fusidic Acid-B (Fusidic Acid and Betamethasone)Kotra Pharma, Malaysia
• BactafuzMankind, India
• Bet Fu (Fusidic Acid and Betamethasone)Medimar, Greece
• Betacort (Fusidic Acid and Betamethasone)CHR. K. Unimed, Cyprus; D.A.S.T Biotech, Greece
• Betafucin (Fusidic Acid and Betamethasone)Delta Pharma, Egypt
• Betafusin (Fusidic Acid and Betamethasone)Pharmex, Greece
• Betasid (Fusidic Acid and Betamethasone)Finixfarm, Greece
• Bio-PorenaIpram, Pakistan
• Canaural (Fusidic Acid and Framycetin, + Prednisolone, + Nystatin (veterinary use))Dechra Veterinary Products, Belgium; VetXX, Austria
• Conoptal (veterinary use)Dermcare-Vet, Australia
• Conoptal Eye (veterinary use)RxVet, New Zealand
• Corticofusidic (Fusidic Acid and Betamethasone)Medizen, Egypt
• DefucinDebeiky, Egypt
• Defucin H (Fusidic Acid and Hydrocortisone)Debeiky, Egypt
• DefuzinXepa-Soul Pattinson, Malaysia
• Defuzin-B (Fusidic Acid and Betamethasone)Xepa-Soul Pattinson, Malaysia
• DermafusinPerffarma, Poland
• DermicinMediphar, Lebanon
• Dermomycin Cort (Fusidic Acid and Triamcinolone)Avantgarde, Italy
• Disuf-B (Fusidic Acid and Betamethasone)Hovid, Hong Kong
• DP Fusidic AcidDouglas, New Zealand
• DrumPharmatrix, Argentina
• Drum β (Fusidic Acid and Betamethasone)Pharmatrix, Argentina
• ErifuralSiegfried, Ecuador
• FacidEskayef, Bangladesh
• Facid HC (Fusidic Acid and Hydrocortisone)Eskayef, Bangladesh
• Facid-BT (Fusidic Acid and Betamethasone)Eskayef, Bangladesh
• FlusterixIasis Pharma, Greece
• Flusterix 2%IASIS Pharmaceuticals Hellas, Cyprus
• FobanAFT, New Zealand; Hoe, Indonesia; Hoe, Malaysia; Hoe Pharma, Singapore; Hoe Pharmaceuticals, Vietnam; HOEPharma, Hong Kong
• Fobancort (Fusidic Acid and Betamethasone)Hoe, Indonesia; Hoe, Malaysia; Hoe Pharma, Singapore; Hoe Pharmaceuticals, Vietnam; HOEPharma, Hong Kong
• Foban-Hydro (Fusidic Acid and Hydrocortisone)Hoe, Malaysia; HOEPharma, Hong Kong
• Fortison (Fusidic Acid and Hydrocortisone)Incepta, Bangladesh
• Fubecot (Fusidic Acid and Betamethasone)Target Pharma, Greece
• Fuci Top 2%Hikma, Egypt
• Fuci Top C (Fusidic Acid and Betamethasone)Hikma, Egypt
• Fucibet (Fusidic Acid and Betamethasone)Euromedicines, Spain; LEO, Ireland; LEO Laboratories, United Kingdom; LEO Pharma, Spain; LEO Pharma, Poland; Ranbaxy, India
• Fucicort (Fusidic Acid and Betamethasone)Abdi Ibrahim, Turkey; bioCSL, New Zealand; Ecosse, Malta; Laboratorio Deutsche Pharma, Chile; LEO, Lebanon; LEO Pharma, Bangladesh; LEO Pharma, Belgium; LEO Pharma, Switzerland; LEO Pharma, Denmark; LEO Pharma, Egypt; LEO Pharma, Finland; LEO Pharma, Greece; LEO Pharma, Hong Kong; LEO Pharma, Hungary; LEO Pharma, Israel; LEO Pharma, Italy; LEO Pharma, Lithuania; LEO Pharma, Malta; LEO Pharma, Malaysia; LEO Pharma, Oman; LEO Pharma, Philippines; LEO Pharma, Portugal; LEO Pharma, Romania; LEO Pharma, Singapore; LEO Pharma, Slovakia; LEO Pharma, Thailand; LEO Pharma, Vietnam; NeoFarma, Malta; Parazelsus Indonesia/LEO Pharma, Indonesia; Roche, Argentina; Roche, Colombia; Roche, Ecuador; Roche, Uruguay; The Star Medicine Importers Co., Cyprus
• Fucicort Lipid (Fusidic Acid and Betamethasone)LEO Pharma, Finland
• Fucicream (Fusidic Acid and Betamethasone)A.G. Therapy, Greece
• FucidU Square Lifesciences, Philippines
• Fucidel 2%Delta Pharma, Egypt
• FucidermLEO, Lebanon
• Fuciderm (Fusidic Acid and Betamethasone (veterinary use))Dechra, Sweden; Dechra Veterinary Products, United Kingdom; Dermcare-Vet, Australia
• Fuciderm for Dogs (Fusidic Acid and Betamethasone (veterinary use))RxVet, New Zealand
• Fucidic Plus (Fusidic Acid and Betamethasone)Sigma, Egypt
• Fucidic Sigma 2%Sigma, Egypt
• FucidinCSL, Australia; Ecosse, Malta; Laboratorio Deutsche Pharma, Chile; LENIS, Slovenia; LEO, Ireland; LEO, Lebanon; LEO, Norway; LEO Laboratories, United Kingdom; LEO Pharma, Bangladesh; LEO Pharma, Belgium; LEO Pharma, Bulgaria; LEO Pharma, Canada; LEO Pharma, Switzerland; LEO Pharma, Czech Republic; LEO Pharma, Denmark; LEO Pharma, Estonia; LEO Pharma, Egypt; LEO Pharma, Greece; LEO Pharma, Hong Kong; LEO Pharma, Hungary; LEO Pharma, Israel; LEO Pharma, Iceland; LEO Pharma, Lithuania; LEO Pharma, Latvia; LEO Pharma, Malta; LEO Pharma, Malaysia; LEO Pharma, Oman; LEO Pharma, Peru; LEO Pharma, Philippines; LEO Pharma, Poland; LEO Pharma, Romania; LEO Pharma, Sweden; LEO Pharma, Singapore; LEO Pharma, Thailand; LEO Pharma, Taiwan; LEO Pharma, Vietnam; Medicem, Malta; P & D, Malta; Parazelsus Indonesia/LEO Pharma, Indonesia; Ranbaxy, India; Roche, Argentina; Roche, Uruguay; The Star Medicine Importers Co., Cyprus
• Fucidin 1%Amdipharm, Cyprus
• Fucidin 2%The Star Medicine Importers Co., Cyprus
• Fucidin H (Fusidic Acid and Hydrocortisone)Ecosse, Malta; LEO Laboratories, United Kingdom; LEO Pharma, Bangladesh; LEO Pharma, Canada; LEO Pharma, Estonia; LEO Pharma, Greece; LEO Pharma, Israel; LEO Pharma, Italy; LEO Pharma, Malta; LEO Pharma, Malaysia; LEO Pharma, Peru; LEO Pharma, Romania; LEO Pharma, Singapore; LEO Pharma, Slovakia; LEO Pharma, Thailand; LEO Pharma, Vietnam; Medicem, Malta; NeoFarma, Malta; Roche, Ecuador; LEO Pharma, Switzerland; LEO Pharma, Hong Kong; LEO Pharma, Hungary; LEO Pharma, Lithuania; LEO Pharma, Philippines; Roche, Argentina; Roche, Colombia
• Fucidin Hydrocortisone (Fusidic Acid and Hydrocortisone)LEO Pharma, Belgium; LEO Pharma, Iceland
• Fucidin LeoLEO Pharma, Egypt; Roche, Ecuador
• FucidineLEO Pharma, France; LEO Pharma, Tunisia
• Fucidine 2%LEO Pharma, France
• Fucidine H (Fusidic Acid and Hydrocortisone)LEO Pharma, Germany; LEO Pharma, Spain; LEO Pharma, Portugal
• Fucidin-H (Fusidic Acid and Hydrocortisone)Laboratorio Deutsche Pharma, Chile; LEO Pharma, Oman
• Fucidin-Hydrocortison (Fusidic Acid and Hydrocortisone)LEO Pharma, Denmark; LEO Pharma, Finland; LEO Pharma, Sweden
• FucimedMedpharma, Lebanon
• FucimycinWinston, Taiwan
• Fucindac-H (Fusidic Acid and Hydrocortisone)Viofar, Greece
• FucinexZuventus, India
• Fuciphac 2%Western, Egypt
• FucitalmicLEO, Lebanon
• FucithalmicAbdi Ibrahim, Turkey; Amco, Singapore; Amdipharm, Belgium; Amdipharm, Denmark; Amdipharm, Norway; Amdipharm, Portugal; Amdipharm, Tunisia; Ecosse, Malta; Laboratorios Andromaco, Chile; Leo Pharma, Austria; PRO FARMA, Switzerland; Roche, Colombia; Amdipharm, Germany
• Fucithalmic (veterinary use)Dechra, Netherlands; Dechra, Sweden; Dechra Veterinary Products, France
• Fucithalmic 1%CSP, France; LEO Pharma, Egypt
• Fucithalmic LeoRoche, Ecuador
• FudionOPP, Oman
• FugenYing Yuan, Taiwan
• FuladicGuardian Pharmatama, Indonesia
• FulijingSen Tai, Taiwan
• FulosinWashington, Taiwan
• FumadexPharmaderm, Tunisia
• FusacidChema-Elektromet, Poland
• Fusacid H (Fusidic Acid and Hydrocortisone)Chema-Elektromet, Poland
• FusextrineConfar, Portugal
• FusiSantiago, India
• Fusi 2%Pharaonia, Egypt
• Fusi Zon (Fusidic Acid and Hydrocortisone)Eimc, Egypt
• Fusi-B (Fusidic Acid and Beclometasone)Santiago, India
• Fusibac-H (Fusidic Acid and Hydrocortisone)Drug International, Bangladesh
• FusibactEast West, India; Jamjoom Pharma, Oman
• Fusibact-B (Fusidic Acid and Betamethasone)East West, India; Jamjoom Pharma, Oman
• Fusibet (Fusidic Acid and Betamethasone)S.M. Farm, Greece
• Fusicort (Fusidic Acid and Hydrocortisone)Opsonin, Bangladesh
• FusicutanDermapharm, Switzerland
• Fusidate H (Fusidic Acid and Hydrocortisone)Aristopharma, Bangladesh; Aristopharma, Hong Kong
• FusidenPanion & BF, Taiwan
• FusiderTai Yu, Taiwan
• FusidermSpimaco, Oman
• Fusiderm 2%Eva, Egypt
• Fusidic Acid 1% AmdipharmAmdipharm Mercury Company, United Kingdom
• Fusidic Acid FocusFocus Pharmaceuticals, United Kingdom
• Fusidic Acid SinpharSinphar, Taiwan
• Fusidic Plus (Fusidic Acid and Hydrocortisone)Beximco, Bangladesh
• Fusidic TargetTarget Pharma, Greece
• Fusidictam 2%Magic ph, Egypt
• Fusidine TevaTeva, Belgium
• Fusidinsyre OrifarmOrifarm Generics, Denmark
• FusifenFourrts, Malaysia
• FusigraGraha, Indonesia
• FusikYuan Chou, Taiwan
• FusimedD & M Pharma, Chile
• Fusimed (Fusidic Acid and Hyaluronic Acid)Cassara, Argentina
• Fusimed B (Fusidic Acid and Betamethasone)Cassara, Argentina
• Fusimed-B (Fusidic Acid and Betamethasone)D & M Pharma, Chile
• FusindacViofar, Greece
• FusiolOlcare Laboratories, India
• FusitalTalent, India
• FusitopHLB Pharma, Argentina
• Fusitrim (Fusidic Acid and Hydrocortisone)Asiatic Lab, Bangladesh
• FuskinSwiss Pharm, Taiwan
• FusonPyridam Farma, Indonesia
• FusotexPatron, Taiwan
• FusqeroStasisport, Portugal
• FusycomCombiphar, Indonesia
• FutadermInterbat, Indonesia
• FutaronSigma, Georgia
• FutasoleJulphar, Egypt; Julphar, Lebanon; Julphar, Oman
• Futasole 2%Julphar, Egypt
• Futasone (Fusidic Acid and Betamethasone)Julphar, Egypt; Julphar, Lebanon; Julphar, Oman
• FutenUBI, Taiwan
• Futhalm 1%Sigma, Egypt
• FutopAdcock Ingram, India
• Futop-B (Fusidic Acid and Betamethasone)Adcock Ingram, India
• GelbioticLKM, Argentina
• Gelbiotic Plus (Fusidic Acid and Betamethasone)LKM, Argentina
• GermacidPharmaniaga, Vietnam
• Halovate-F (Fusidic Acid and Ulobetasol)Glenmark, India
• Hoebedic (Fusidic Acid and Betamethasone)Hoe, Philippines
• HopaqHoe, Philippines
• Hydrofusin (Fusidic Acid and Hydrocortisone)Exelixis, Greece
• HyloseptAxxon, Poland
• Infloc 2%S.F.D., Portugal
• Isaderm (Fusidic Acid and Betamethasone (veterinary use))Albrecht, Germany; Dechra, Finland; Dechra Veterinary Products, Belgium; Dechra Veterinary Products A/S, Ireland; Gräub, Switzerland
• Isathal (veterinary use)Albrecht, Germany; Dechra, Norway; Dechra Veterinary Products A/S, Ireland; Gräub, Switzerland
• Isathal 1% (veterinary use)Dechra, Finland
• Momate-F (Fusidic Acid and Mometasone)Glenmark, India
• NadicloxMedinfar, Portugal
• NiofenMediderm, Peru
• Optifucin 1%Api, Egypt
• Pharmaniaga Fusidic B (Fusidic Acid and Betamethasone)Pharmaniaga, Malaysia
• PhudicinBright Future, China; Bright Future Pharm, Hong Kong
• QualifutinQuality Pharm, Hong Kong
• Sensibio (Fusidic Acid and Betamethasone)Iasis Pharma, Greece
• Shinsox ViscourPatron, Taiwan
• SofinoxApex, India
• Staficort (Fusidic Acid and Betamethasone)Mentiterm, Greece
• StafineKoçak, Turkey
• Stafine-cort (Fusidic Acid and Betamethasone)Koçak, Turkey
• StanicidHemofarm, Bosnia & Herzegowina
• StaphidermTrima, Israel
• TopidicPharma International, Lebanon; Pharma International, Oman
• Topizone (Fusidic Acid and Betamethasone)Pharma International, Lebanon; Pharma International, Oman
• TopocidPharma International, Oman
• TricidineWest Pharma, Tunisia
• Trigoderm (Fusidic Acid and Betamethasone (veterinary use))Dechra Veterinary Products, United Kingdom; Dechra Veterinary Products A/S, Ireland
• UcidermPhiladelphia, Oman; Simed, Tunisia
• Uciderm Plus (Fusidic Acid and Betamethasone)Simed, Tunisia
• Uciderm-B (Fusidic Acid and Betamethasone)Philadelphia, Oman
• Verutex B (Fusidic Acid and Betamethasone)Roche, Brazil
• Xzema (Fusidic Acid and Betamethasone)Orion, Bangladesh
• ZetaTabuk, Lebanon; Tabuk Pharmaceutical, Oman
• Zeta Cort (Fusidic Acid and Betamethasone)Tabuk, Lebanon
• Zeta-Cort (Fusidic Acid and Betamethasone)Tabuk Pharmaceutical, Oman
• Canaural (Fusidic Acid and Framycetin, + Prednisolone, + Nystatin (veterinary use))Dechra, Finland; Dechra, Norway; Dechra, Sweden; Dechra Veterinary Products, France; Dechra Veterinary Products, United Kingdom; Dechra Veterinary Products A/S, Ireland; Dermcare-Vet, Australia; Gräub, Switzerland; RxVet, New Zealand
• AffusineWill, Netherlands
• Fucicort (Fusidic Acid and Betamethasone)LEO Pharma, Bulgaria; LEO Pharma, Czech Republic; LEO Pharma, Germany; LEO Pharma, Estonia; LEO Pharma, Latvia; LEO Pharma, Mexico
• Fucicort Lipid (Fusidic Acid and Betamethasone)LEO Pharma, Germany
• Fuciderm (Fusidic Acid and Betamethasone (veterinary use))Dechra Veterinary Products, Austria; Dechra Veterinary Products, Israel
• FucidinLEO, Ireland; LEO Pharma, Netherlands
• Fucidin H (Fusidic Acid and Hydrocortisone)LEO, Ireland; LEO Pharma, Bulgaria; LEO Pharma, Czech Republic; LEO Pharma, Latvia
• FucidineLEO Pharma, Germany
• Fucidin-Hydrocortison (Fusidic Acid and Hydrocortisone)LEO, Norway
• FucithalmicAbcur, Sweden; Al Pharm, South Africa; Amdipharm, Ireland; Amdipharm, Malta; Amdipharm, Netherlands; Euro Registratie, Netherlands; Fisher Farma, Netherlands; LEO Pharma, Bulgaria; LEO Pharma, Czech Republic; LEO Pharma, Germany; LEO Pharma, New Zealand; LEO Pharma, Oman; LEO Pharma, Slovakia; Medicem, Malta
• Fucithalmic (veterinary use)Dechra Veterinary Products, Israel
• Fucithalmic 1%Amdipharm Mercury Company, United Kingdom
• FusicutanDermapharm, Germany
• Fusidinezuur Basic PharmaBasic Pharma, Netherlands
• Fusidinezuur CFCentrafarm, Netherlands
• Fusidinezuur FocusFocus Care, Netherlands
• Fusidinsäure acisacis, Germany
• Isaderm (Fusidic Acid and Betamethasone (veterinary use))Dechra, Norway
• AfucidFerron, Indonesia
• Axcel Fusidic AcidKotra Pharma, Malaysia
• Axcel Sodium FusidateKotra Pharma, Malaysia
• ConlifuWinston, Taiwan
• DermafusinPerffarma, Poland
• DermomycinAvantgarde, Italy
• DisfectUBI, Taiwan
• DisufHovid, Hong Kong
• FobanAFT, New Zealand; Hoe, Malaysia
• Fobancort (Fusidic Acid and Betamethasone)Hoe Pharmaceuticals, Vietnam
• ForsudermWooridul Life Sciences, Singapore
• Forudine (veterinary use)Dechra Veterinary Products, France
• FucidinAbdi Ibrahim, Turkey; Al Pharm, South Africa; CSL, Australia; Euro Registratie, Netherlands; Fisher Farma, Netherlands; LEO, Ireland; LEO, Norway; LEO Laboratories, United Kingdom; Leo Pharma, Austria; Leo Pharma, Denmark; Leo Pharma, Mexico; Medicem, Malta; NeoFarma, Malta; Parazelsus Indonesia/LEO Pharma, Indonesia; Pharma-Cos, Malta; Roche, Argentina; Roche, Uruguay; Central Procurement & Supplies Unit, Malta
• Fucidin IntertulleLaboratorio Deutsche Pharma, Chile; LEO Pharma, Hong Kong
• Fucidin LeoLEO Pharma, Israel; Roche, Ecuador
• Fucidin Leo 2%Daiichi Sankyo, Japan
• FucidineEuro Registratie, Netherlands; LEO Pharma, Germany; LEO Pharma, Spain; LEO Pharma, France; LEO Pharma, Portugal
• FucilexMolex Ayus, Indonesia
• FudikinSamjin, Singapore
• FudinDong Kook, Taiwan
• FuladicGuardian Pharmatama, Indonesia
• FusibactJamjoom Pharma, Oman
• FusidateAristopharma, Bangladesh; Aristopharma, Hong Kong
• FUSIDATE DE SODIUM ESSENTIAL PHARMAEssential Pharma Ltd, France
• Fusidate De Sodium Pierre Fabre 2%Pierre Fabre Médicament, France
• Fusidato de Sodio IsdinIsdin, Spain
• FusidermSpimaco, Oman
• FusigenGeno Pharmaceuticals Ltd, Myanmar
• FusodateUnion, Taiwan
• FusonPyridam Farma, Indonesia
• FusycomCombiphar, Indonesia
• FutadermInterbat, Indonesia
• HopaqHoe, Philippines
• KangfujingSen Tai, Taiwan
• NadicloxFarmigea, Georgia
• Pharmaniaga FusidicPharmaniaga, Malaysia
• RobisidTripharma, Turkey
• SofuniUBI, Taiwan
• StafineKoçak, Turkey
• StanicidHemofarm, Serbia
• VerutexRoche, Brazil
• WoncareHovid, Philippines
• ZetaTabuk Pharmaceutical, Oman

Glossary

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

www.drugs.com

Fusidine | Fusidic acid | 6990-06-3 Active Pharmaceutical Ingredients of Antibiotics

Fusidine | Fusidic acid | 6990-06-3 Active Pharmaceutical Ingredients of Antibiotics for sale

1. Fusidine basic infor:

Product name: Fusidine

Other Names:Fusidic acid;Fusidine

Category: Antibiotics >Other antibiotic Drugs >Fusidine

CAS: 6990-06-3

EINECS: 230-256-0

Molecular formula: C31h58O6

Molecular weight: 516.72

2. Fusidine chemical properties:

Appearance: White crystalline powder

Assay:98.2%min

Melting point 190-192°C

Quality standard: EP8.0

Packing: 1kg/foil bag or as required

3. What is Fusidine?

Fusidic acid is a bacteriostatic antibiotic. Fusidic Acid suppresses nitric oxide lysis of pancreatic islet cells. Inhibits protein synthesis in prokaryotes by inhibiting the ribosome-dependent activity of G factor and translocation of peptidyl-tRNA.

4. Fusidine uses

Fusidic acid is highly sensitive to a variety of Gram-positive cocci associated with skin infections, especially for Staphylococcus aureus; and it is also effective for the resistant Staphylococcus aureus, and also for certain Gram-negative bacteria. No cross-resistance with other antibiotics

5. APIs of Antibiotic drugs:

Azithromycin (CAS NO.83905-01-5)Amikacin Sulphate (39831-55-5)Erythromycin (114-07-8)Chloramphenicol (56-75-7)Clarithromycin (81103-11-9)Dirithromycin (62013-04-1)Tacrolimus (104987-11-3)Roxithromycin (80214-83-1)Rifabutin (72559-06-9)Rifaximin (80621-81-4)Clindamycin Phosphate (24729-96-2)Potassium clavulanate (61177-45-5)Moxifloxacin hydrochloride (186826-86-8)Nifuroxazide (965-52-6)Nitazoxanide (55981-09-4)Secnidazole (3366-95-8)Vancomycin hydrochloride (1404-93-9)Bacitracin (1405-87-4)Minocycline hydrochloride (13614-98-7)Lincomycin hydrochloride (859-18-7)

6. How to order quickly and safely ?

RegardsSales managerAnna HuangNanjing Bangnuo Biotechnology Co., LtdRoom 901 Tianqinwan Garden NO.1008 Ssangyong Avenue , Jiangning District , Nanjing City , Jiangsu Province , P.R.China . (211100)Email: [email protected]: +8617327094661(What's app)Skype:bnsteroidWebsite: www.realanabolicsteroids.com

TAG

Fusidine

Fusidic acid

Fusidine dressing

Fusidine can use pimple

www.realanabolicsteroids.com

Fusidic acid - an overview

Fusidic Acid

Fusidic acid has a steroidal chemical structure.

Mechanism of Action

It inhibits protein synthesis by binding to the ribosome elongation factor G complex (see Chapter 137).

Spectrum of Activity

Fusidic acid has a narrow spectrum of activity. It exhibits good activity against staphylococci including both methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus (MSSA and MRSA), as well as coagulase-negative staphylococci, but activity against other gram-positive cocci is poor. In addition, fusidic acid has anaerobic activity (including Clostridium difficile), has been found to be active against some mycobacteria and has limited activity against Legionella pneumophila.1

Mechanisms of Resistance

High-level resistance in Staph. aureus is conferred through mutations in the gene encoding elongation factor G. Several transferable mechanisms of resistance result in low-level resistance (see Chapter 138).2

Pharmacokinetics, Route of Administration and Dosage

Fusidic acid is available for intravenous (IV), oral or topical administration. The bioavailability after oral administration is 75–90% with tablets but only about 23% in children given a suspension.3 It has high inter-patient variability in pharmacokinetics, is almost entirely nonrenally eliminated by biliary excretion and is highly protein-bound (97%).

Conventional dosages are as follow:

adults: 500 mg (as sodium fusidate tablets) q8h orally or intravenously;

neonates: 50 mg/kg (as fusidic acid suspension) in three divided doses;

children 1 month–1 year old: 15 mg/kg q8h;

children 1–5 years old: 250 mg q8h;

children 6–12 years old: 500 mg q8h.

Due to slow attainment of steady state, the use of loading doses (≥1200 mg twice daily on day 1 followed by ≥600 mg q12 h) was recently proposed to increase activity and prevent emergence of resistance.4

Doses should be reduced in patients who have hepatic and/or biliary disease. Full doses can be given to patients who have renal insufficiency and to the elderly. Because of its high protein binding, fusidic acid should be avoided in women in the third trimester of pregnancy and newborns to decrease the risk of kernicterus.

Indications

Fusidic acid is mainly used as an antistaphylococcal agent but has to be used in combination with other antibiotics to prevent the emergence of resistance during systemic treatment. Resistance has also emerged as a problem clinically when it has been used as a single agent topically for skin infections.5

Both in vivo and in vitro studies have shown that the antibacterial activity of the combination of fusidic acid with other antibiotics is unpredictable so that synergistic, antagonist, additive or indifferent effects have all been described.6,7 For instance, in an experimental model of Staph. aureus meningitis, antagonism between methicillin and fusidic acid was observed.8

Fusidic acid is widely used for the treatment of bone and joint infections due to Staph. aureus as high bactericidal levels are achieved in infected joints and bone, including sequestra. It is usually combined with a penicillinase-stable penicillin (e.g. dicloxacillin or flucloxacillin) to prevent the emergence of resistance, although data from clinical trials are not available.

Fusidic acid is one of the few oral agents available for the treatment of methicillin-resistant staphylococci. Ideally it should be used in combination with another antibiotic to prevent the emergence of resistance. Oral rifampin (rifampicin) and fusidic acid have been used successfully together for MRSA decolonization and follow-up oral treatment of prosthetic joint infections, but monitoring of liver function is advisable as hepatic failure has been described with this combination.9

Adverse Reactions and Interactions

Fusidic acid has a good safety profile. Table 149-1 lists the most important adverse reactions to fusidic acid. Most common adverse reactions are minor (diarrhea, abdominal discomfort). Intravenous fusidic acid may cause thrombophlebitis, but this risk has decreased with newer intravenous formulations. Additionally, intravenous use appears to increase the risk of jaundice and liver impairment. In newborns, fusidic acid may cause kernicterus. Fusidic acid may interact with coumarin derivatives and oral contraceptives, reducing the bioavailability of these drugs.

www.sciencedirect.com

Смотрите также

• 
  Эндолюмбальное введение антибиотиков
• 
  Фенотропил и антибиотики
• 
  Месалазин это антибиотик
• 
  Антибиотики от мигрени
• 
  Антибиотики задерживают воду
• 
  Антибиотики в армии
• 
  Амоксил антибиотик цена
• 
  Антибиотики и газировка
• 
  Бели от антибиотиков
• 
  Антибиотик монурал отзывы
• 
  Спринцевание с антибиотиками